Biopharma company Kiniksa goes public
Bermuda and Lexington, Massachusetts-based Kiniksa Pharmaceuticals, a biopharmaceutical company, has raised about $152.6 million for its IPO after pricing its over 8.4 million shares at $18 per share. The stock began trading May 24, 2018 on the NASDAQ under the ticker symbol “KNSA.” Goldman Sachs and J.P. Morgan Securities LLC are the lead underwriters. Kiniksa's pre-IPO backers included Baker Brothers and Arrowpoint Funds.
24 May 2018•2 mins read
